Piramal Pharma Solutions (PPS), a part of Piramal Pharma, has announced plans to invest $80m to expand its Lexington, Kentucky facility in the US.
This site focuses on sterile compounding, liquid filling, and lyophilisation for sterile injectable drugs.
The expansion will add 24,000ft2 of manufacturing space to the Lexington site, and a new laboratory and advanced machinery to scale clients’ products.
Other key upgrades include a new filling line, two commercial-sized lyophilisers, a specialised capping machine, and an external vial washer.
Currently, the facility produces 104 product batches per year at peak capacity. By Q1 2027, this capacity is expected to increase to over 240 batches annually.
The expansion supports Piramal Pharma Solutions’ ADCelerate programme for antibody-drug conjugate (ADC) development and manufacturing.
Financed through bank loans and internal funds, the investment will boost the site’s capacity and capabilities to meet the growing market demand.
With this expansion, Piramal Pharma aims to strengthen its position as a global partner in biologic manufacturing.
Piramal Pharma chairperson Nandini Piramal said: “This expansion represents a strategic investment in the future of Piramal Pharma.
“Filling the commercial manufacturing gap enables the Lexington site to access the rapidly expanding injectables market and establish itself as a key player in the segment.”
According to Piramal Pharma Solutions, the investment will boost the local economy, creating over 40 full-time jobs. It will also foster economic development and help create a diverse workforce in the area.
Commerce Lexington president and CEO Bob Quick said: “Piramal Pharma Solutions’ decision to expand its Lexington operations is a significant step forward for our region’s economic growth.
“This investment not only demonstrates Piramal Pharma’s confidence in our community and workforce but also underscores Lexington’s position as a prime location for innovative companies to grow and thrive.”
Piramal Pharma Solutions is a contract development and manufacturing organisation (CDMO) that provides end-to-end solutions throughout the drug life cycle. The firm has a global network of facilities in North America, Europe, and Asia.
The CDMO offers drug discovery solutions, process development, clinical trial supplies, and commercial supply of active pharmaceutical ingredients (APIs) and finished dosage forms.
Additionally, Piramal Pharma Solutions provides development and manufacturing services for biologics, including vaccines and gene therapies, through its associate company, Yapan Bio.
In December 2023, the CDMO opened its expanded ADC manufacturing site in Grangemouth, Scotland.
